NCT05533697 2026-04-03
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
ModernaTX, Inc.
CytomX Therapeutics
Bristol-Myers Squibb
Anaveon AG
SQZ Biotechnologies
SQZ Biotechnologies